* If you want to update the article please login/register
Breast cancer survivors with early stage, HER2 low, and hormone receptor positive breast cancer are among the treatment arm with the highest likelihood of success, based on pathologic complete response rate. After a single cycle of targeted therapy, the molecular changes in tumor biomarkers, including Ki67, have been determined. The European Organization for Research and Treatment of Cancer Quality-of Life Questionnaire (Core 30), a questionnaire that collects quality of life by determining toxicity burden using a quality of life /patient reported findings questionnaire. On day 1 of each subsequent cycle, patients receive trastuzumab deruxtecan intravenously over 90 minutes. Patients receive trastuzumab deruxtecan IV over 90 minutes on cycle 1 and 30 minutes on day 1 of each subsequent cycle and anastrozole orally on days 1-21. Patients are followed up at 21-28 days after completion of research study.
Source link: https://clinicaltrials.gov/ct2/show/NCT04553770
* Please keep in mind that all text is summarized by machine, we do not bear any responsibility, and you should always check original source before taking any actions